U.K. AI imaging firm Brainomix has entered into a partnership with German pharmaceutical company Boehringer Ingelheim to improve the care of U.S. patients with fibrosing lung disease.
This project will focus on the opportunity for AI imaging analysis using Brainomix 360 e-Lung on routine CT scans to speed up diagnosis, improve access to treatment for people living with this disease, and overcome challenges tied to identifying patients who may be eligible for treatment based on imaging.
Through the partnership, Brainomix will deploy its e-Lung software, which has 510(k) clearance from the U.S. Food and Drug Administration (FDA), to U.S. pulmonology centers and their networks of referring sites. The data generated will help validate the clinical value of e-Lung, highlighting the potential of digital technology to improve care and outcomes for people with fibrosing lung disease, the company said.
